Ethicon

Avanos Medical, Inc. Appoints Sig Delgado as Senior Vice President, Integrated Supply Chain

Retrieved on: 
월요일, 5월 13, 2024
Cordis, Ethicon, J&J, Avanos, Engineering, AVNS, Florida International University, Massachusetts Institute of Technology, Avanos Medical, Management

ALPHARETTA, Ga., May 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Sigfrido (Sig) Delgado has been appointed senior vice president, integrated supply chain.

Key Points: 
  • ALPHARETTA, Ga., May 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Sigfrido (Sig) Delgado has been appointed senior vice president, integrated supply chain.
  • In this role, Delgado will lead the teams focused on implementing continuous improvements within the Company's end-to-end supply chain capabilities worldwide.
  • Delgado joins Avanos from Jabil Healthcare, the industry's largest global provider of healthcare manufacturing solutions, where he most recently served as vice president of its global medical technology business.
  • Delgado earned a bachelor's degree in mechanical engineering from Massachusetts Institute of Technology and a master's degree in engineering management from Florida International University.

Gynesonics Announces Key Executive Appointments to Further Accelerate and Expand Adoption of the Sonata Treatment

Retrieved on: 
화요일, 3월 19, 2024
Principal, Spherion, Uterine fibroid, Organization, Growth, Health, Diabetes, Business administration, Patient, Xavier University, Medtronic, Engineering, Senior, McKesson Corporation, Woman, Marketing, Michigan State University, Minnesota State University Moorhead, Market access, Ethicon, Human resources, Management

The addition of these executive team members will support the company’s continued growth and adoption of the innovative Sonata Treatment.

Key Points: 
  • The addition of these executive team members will support the company’s continued growth and adoption of the innovative Sonata Treatment.
  • Commenting on these appointments, Skip Baldino, President and Chief Executive Officer of Gynesonics said, “I am very pleased to welcome Ted Stephens, Keith Chrzanowski, and Laurie Sandberg to Gynesonics.
  • Their collective contributions will help further accelerate adoption of the Sonata Treatment and help deliver on our commitment to provide women with a safe, effective alternative to more invasive treatment options for symptomatic fibroids.”
    Mr. Ted Stephens joins Gynesonics as its Chief Marketing and Strategy Officer.
  • Prior to joining Gynesonics he provided outstanding human resource and operational leadership to achieve success within several industries.

LivaNova Reports Fourth-Quarter and Full-Year 2023 Results

Retrieved on: 
수요일, 2월 21, 2024
Mental Health, Health, Medical Devices, Neurology, Health Technology, Cardiology, Biotechnology, Telephone, News, ACS, Growth, Kozy, Table, Interim, Ethicon, LivaNova, Circulatory system, Neuromodulation, Wind

On a U.S. GAAP basis, full-year 2023 operating loss was $68.5 million, as compared to operating loss of $76.8 million for full-year 2022.

Key Points: 
  • On a U.S. GAAP basis, full-year 2023 operating loss was $68.5 million, as compared to operating loss of $76.8 million for full-year 2022.
  • Adjusted operating income for full-year 2023 was $169.3 million, as compared to adjusted operating income of $145.1 million for full-year 2022.
  • On a U.S. GAAP basis, full-year 2023 diluted earnings per share was $0.32, as compared to diluted loss per share of $1.61 for full-year 2022.
  • Full-year 2023 adjusted diluted earnings per share was $2.80, as compared to adjusted diluted earnings per share of $2.39 for full-year 2022.

NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation

Retrieved on: 
목요일, 2월 22, 2024
Esophagitis, Tricuspid valve, Denervation, General partnership, Mitral regurgitation, Johnson & Johnson, Mayo Clinic, Clinical professor, Hypertension, Ethicon, Mitral valve, Patient, Disease, Pharmaceutical industry

MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.

Key Points: 
  • MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.
  • The company appointed Todd Berg as Chief Executive Officer to oversee clinical and commercial programs for transeptal and transapical repair of damaged mitral valve chords resulting in regurgitation.
  • Berg has over 30 years of experience successfully developing and commercializing novel medical therapies and holds over 100 U.S. patents.
  • The opportunity to develop a first-line therapy for mitral valve disease, by resolving regurgitation early in the disease state, is incredibly compelling," said Berg.

NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation

Retrieved on: 
목요일, 2월 22, 2024
Esophagitis, Tricuspid valve, Denervation, General partnership, Mitral regurgitation, Johnson & Johnson, Mayo Clinic, Clinical professor, Hypertension, Ethicon, Mitral valve, Patient, Disease, Pharmaceutical industry

MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.

Key Points: 
  • MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.
  • The company appointed Todd Berg as Chief Executive Officer to oversee clinical and commercial programs for transeptal and transapical repair of damaged mitral valve chords resulting in regurgitation.
  • Berg has over 30 years of experience successfully developing and commercializing novel medical therapies and holds over 100 U.S. patents.
  • The opportunity to develop a first-line therapy for mitral valve disease, by resolving regurgitation early in the disease state, is incredibly compelling," said Berg.

Students graduating with a Rutgers MBA benefit from robust New Jersey job market

Retrieved on: 
목요일, 2월 22, 2024
University of Mumbai, Rutgers University, Stony Brook University, Multimedia, Garden State, Marketing, Health, Dell, Johnson & Johnson, Sood, MBA, Curriculum, Food, Mathematics, Learning, Garden, Mentorship, City, Ethicon, Military, Employment, Dell Technologies, Pace University, Finance, Telecommunications, Financial Times, Software, Student, Management

NEWARK, N.J., Feb. 22, 2024 /PRNewswire/ -- With a booming economy in the state of New Jersey and the close proximity to New York City, Rutgers Business School  MBA graduates are taking advantage of a robust job market.

Key Points: 
  • NEWARK, N.J., Feb. 22, 2024 /PRNewswire/ -- With a booming economy in the state of New Jersey and the close proximity to New York City, Rutgers Business School MBA graduates are taking advantage of a robust job market.
  • Most Rutgers Full-Time MBA graduates find a job in New Jersey in part because it has experienced some of the fastest job growth of any state in the Northeast.
  • "The unsung hero is the New Jersey economy," said Dean Vera, assistant dean and director, MBA Office of Career Management at Rutgers Business School.
  • The median starting base salary after graduation (in 2022) for full-time Rutgers MBA students was $113,500 according to Vera.

LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director

Retrieved on: 
월요일, 2월 5, 2024
Medical Devices, Health, Hospitals, Surgery, Health Technology, Biotechnology, Business administration, Interim, Advisory board, PLC, Kozy, Patient, Ethicon, LIVN, Singapore Management University, LivaNova, Health administration, University, Johnson & Johnson, Management

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a member of the Board of Directors, effective March 1, 2024.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a member of the Board of Directors, effective March 1, 2024.
  • Makatsaria most recently served as Company Group Chairman at Johnson & Johnson MedTech, leading its global Ethicon surgery business.
  • “Vlad is a respected leader in the medical device industry with a proven reputation for delivering results, driving innovation and building great teams,” said Bill Kozy, LivaNova Board Chair.
  • Kozy will continue in his role as LivaNova Board Chair.

Ethicon Introduces ETHIZIA™ Hemostatic Sealing Patch, Clinically Proven to Stop Disruptive Bleeding

Retrieved on: 
수요일, 11월 15, 2023
Acquisition, Surgeon, Clinical trial, Patient, CE marking, GATT, Hemostasis, LATAM, Fibrin, Ethicon

RARITAN, N.J., Nov. 15, 2023 /PRNewswire/ -- Ethicon*, a Johnson & Johnson MedTech company**, today announced the approval of ETHIZIA™, an adjunctive hemostat solution which has been clinically proven to achieve sustained hemostasis in difficult to control bleeding situations.1 Comprised of unique synthetic polymer technology, ETHIZIA™ Hemostatic Sealing Patch is the first and only hemostatic matrix designed to be equally active and efficacious on both sides***.2 Designed for maximum adaptability, it can be stuffed, rolled, pulled apart, trimmed and tailored,3, 4 making it easy to handle in both open and minimally invasive surgeries.5 In 80% of clinical trial patients studied****, ETHIZIA™ Hemostatic Sealing Patch stopped bleeding in 30 seconds, an average of six times faster than the leading Fibrin Sealant Patch*****.6 7

Key Points: 
  • "As a global leader in surgery, we are committed to empowering healthcare providers to safeguard patients from surgical complications by continuously delivering breakthrough solutions," said Vladimir Makatsaria, Company Group Chairman, Ethicon.
  • "Disruptive bleeding can contribute to serious complications, and with the addition of ETHIZIA™ to our portfolio, we are well positioned to deliver critical hemostasis solutions for patients."
  • In May 2022, Ethicon acquired GATT Technologies B.V., a Netherlands-based company using differentiated synthetic polymer to create hemostatic and sealant products to address complex surgical bleeding and leak challenges.
  • As a global leader in surgery, Ethicon harnesses deep expertise to design surgical solutions that are smarter, less invasive, and more personalized.

TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS

Retrieved on: 
목요일, 11월 9, 2023
University of Los Andes (Colombia), IPO, Biogen, Therapy, Tajikistan State University of Law, Business, & Politics, Tree, Doctor of Philosophy, MBA, Engineering, HEC Paris, Central Executive Committee (PAP), Politics, Growth, Trinity College, Medicine, Paris, Executive Committee, Business, Senior, University of Hamburg, Ethicon, University, Trinity College Dublin, Sanofi, International communication, La Jolla Institute for Immunology, Immunology, Management, Bayer, Merck

BORDEAUX, France, Nov. 9, 2023 /PRNewswire/ -- TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on a disruptive proprietary technology platform, today announced the appointment of three new members to the Executive Team.

Key Points: 
  • "Since our inception in 2018, TreeFrog has made great strides, and I am proud of the progress the teams have made in our therapeutic programs, technology and partnerships.
  • We are part of the revolution in medicine, pioneering therapeutics and technology in cell therapy.
  • Reinforcing the Executive Committee team is crucial for the next phase in our future growth," Frederic Desdouits, PhD, CEO of TreeFrog Therapeutics.
  • For further information on the Executive Committee, visit www.treefrog.fr

TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS

Retrieved on: 
목요일, 11월 9, 2023
University of Los Andes (Colombia), IPO, Biogen, Therapy, Tajikistan State University of Law, Business, & Politics, Tree, Doctor of Philosophy, MBA, Engineering, HEC Paris, Central Executive Committee (PAP), Politics, Growth, Trinity College, Medicine, Paris, Executive Committee, Business, Senior, University of Hamburg, Ethicon, University, Trinity College Dublin, Sanofi, International communication, La Jolla Institute for Immunology, Immunology, Management, Bayer, Merck

BORDEAUX, France, Nov. 9, 2023 /PRNewswire/ -- TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on a disruptive proprietary technology platform, today announced the appointment of three new members to the Executive Team.

Key Points: 
  • "Since our inception in 2018, TreeFrog has made great strides, and I am proud of the progress the teams have made in our therapeutic programs, technology and partnerships.
  • We are part of the revolution in medicine, pioneering therapeutics and technology in cell therapy.
  • Reinforcing the Executive Committee team is crucial for the next phase in our future growth," Frederic Desdouits, PhD, CEO of TreeFrog Therapeutics.
  • For further information on the Executive Committee, visit www.treefrog.fr